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This study undertakes an analysis of external sourcing of knowledge by biotechnology companies. It suggests that biotech-
nology companies need to be more realistic about R&D operational models in a context where technological changes are 
only incremental and companies based solely on single technology platforms are highly inefficient. It is argued that in order 
to build, preserve or enhance their knowledge creation capabilities in a fast changing environment, firms increasingly 
combine internal ‘‘core’’ capabilities with externally acquired ‘‘complementary’’ ones. Knowledge creation requires in 
reaching the right balance between exploration and exploitation. It consists of activities within the firm in order to create 
knowledge from its own experience and from the experience of other firms, and on the exploitation of that knowledge to 
fulfill the mission of the firm. Thus, a biotechnology company’s ability to choose technologies wisely will have a large im-
pact on the performance of its R&D organization in terms of time to market, productivity, and product quality.  
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1. Introduction 
Sophisticated techniques such as genomics, combinato-
rial chemistry, bioinformatics, functional genomics, pro-
teomics and automated target validation have 
revolutionized the biotechnology industry’s approach to 
drug discovery. The constant creation of new fields 
within the biotechnology field has been a key driver with 
respect to the aggressive growth experienced by this 
sector. The development of cutting-edge technology and 
know-how in academic research institutions has created 
a favourable environment for the creation of early-stage 
biotechnology companies (Figure 1). However, such 
changes in the drug discovery process have considerably 
disrupted the competitive dynamics in the drug discov-
ery industry by dispersing innovation activity (Audretsch 
and Feldman, 2003; Chesbrough, 2003). In effect, the 
number of biotechnology companies reached 4,275 in 
2006 of which 710 were public companies. Europe ac-
counted for 1,465 private and 156 public companies 
while the US accounted for 1,116 private and 336 public 
companies (Lawrence, 2007).  
 
Figure 1. Biotechnology sector’s knowledge base 
Figure 1. Sophisticated novel approaches and technologies in the discovery and design of new drugs have replaced the 
traditional methods of discovery and development. However, such high technology methods in the field of biotechnology 
have mainly contributed to the complexity of the drug discovery process through the generation of a gigantic amount of 
data.  Furthermore, the incremental value-added nature of each technology favours strategies capable of better integrating 
processes and managing resources through a range of different technologies. 
 
Despite the promise of new technologies and tools drug 
development and discovery has not changed significantly 
in the past three decades and the sector’s initial impact 
for new therapies has involved a limited class of prod-
ucts characterized by therapeutic proteins and mono-
clonal antibodies (Walsh, 2003a; Walsh, 2006). 
Undoubtedly, the introduction of such technologies to 
improve R&D productivity by such research intensive 
companies has contributed to our better understanding 
of the molecular mechanisms of diseases. However, the 
biotechnology industry is confronted with the same 
obstacles faced by the pharmaceutical industry in terms 
of long development times ranging from 10 to 15 years 
for novel therapeutics reaching the marketplace; high 
attrition rates; increasing costs and low R&D productiv-
ity. Moreover, the introduction of a wide range of 
J. Technol. Manag. Innov. 2009, Volume 4, Issue 2 
56 
ISSN: 0718-2724. (http://www.jotmi.org) 
Journal of Technology Management & Innovation © Universidad Alberto Hurtado, Facultad de Economía y Negocios 
automated high-throughput technologies has mainly 
contributed in increasing the complexity of drug discov-
ery and the sector’s overall R&D productivity remains 
low (Biocentury Extra, 2000). This has resulted in an-
abundance of drug candidates which does not necessar-
ily mean a marked increase in productivity as the num-
ber of new active compounds launched each year by the 
industry has stayed roughly the same (Hughes, 2008).  
Also, the environment of drug discovery and develop-
ment has rendered innovative capabilities of a biotech-
nology company further uncertain since it is influenced 
by financing and competitive constraints requiring 
enormous R&D investments with uncertain pay-offs. 
Moreover, innovation is essential to the competitive 
survival and lays the foundation of a biotechnology 
company’s strategy formulation in transforming knowl-
edge-based assets into marketed products (Nicholls-
Nixon and Woo, 2003; Schweizer, 2005). However, in a 
constantly changing environment, implementing a suc-
cessful strategy depends to a significant degree on learn-
ing with new directions and on recognizing 
opportunities that materialize during the process. In 
such a context, external sourcing helps multiply oppor-
tunities of discovery, provide the requisite flexibility that 
enables the firm to win the race against time and to 
increase the chances of product success. 
Some explanation has been provided notably through 
the resource-based view of the firm (Peteraf, 1993) that 
stipulates that heterogeneity of resources and capabili-
ties is essential for achieving competitive advantage 
(Dierickx and Cool, 1989; Newbert, 2007). Authors 
have mainly highlighted the acquisition of externally 
complementary assets by securing inter-firm strategic 
collaborations (Cockburn and Henderson, 1998; 
Coombs and Hull, 1998; Pisano, 1990; Rigby and Zook, 
2002) and M&A transactions (Ahuja and Katila, 2001; 
Prabhu, Chandy and Ellis, 2005). Others have examined 
how variations in innovation performance by the firm 
affect the strategic positioning of firms competing for 
resources (Gulati, Nohria and Zaheer, 2000). 
Although there now exists a body of work on external 
knowledge acquisition in the innovation literature, much 
of it tends to focus mainly on the scientific division of 
labour between major pharmaceutical companies and 
biotechnology companies, universities and public re-
search institutes, (Henderson and Cockburn, 1996; 
Owen-Smith et al., 2002; McKelvey et al., 2004). It has 
been argued that strategic alliances may be the pre-
ferred choice of external technology acquisition over 
other modes of collaborations such as mergers & acqui-
sitions as only desired resources are acquired (Das and 
Teng, 2000).  
The particular challenge facing early-stage biotechnology 
companies is that a wide range of tools, technologies 
and approaches need to be combined and applied to the 
search for new and improved therapeutics. To compli-
cate things further a high proportion of these technolo-
gies and related intangible assets have unproven R&D 
productivity. In a R&D outsourcing environment, due to 
discrepancies in data integrity and harmonization strate-
gic alliances contribute mainly to the dispersion of the 
product information flow from one stage to another 
within the value chain of the drug discovery process. 
This presents a dramatic challenge for an early stage 
biotechnology company since the largest value to be 
captured resides in innovations that affect the later 
stages of drug development. The main issue that needs 
to be resolved is improving the probability of success of 
clinical trials which only manifest itself only many years 
later. Firms need to avoid misconceptions about accel-
erated drug development that has compromised the 
completeness of development and favoured diminished 
quality.  
Moreover, the increasing pace of biological discoveries 
has shifted the productivity bottleneck downstream in 
the drug development process. Even with greater effi-
ciency in lead identification and optimization, improve-
ments will also need to be made in clinical development 
and the overall speed to market. In this environment, 
biotechnology companies need to focus on their future 
markets in order to stay ahead of the game. Ultimately, 
the objective for a drug discovery company is not nec-
essarily to provide definitive answers in early preclinical 
stages. The definitive answer is really at the end of the 
clinical trials. What a drug discovery company needs to 
achieve early on is to proceed to a rank-ordering exer-
cise and select the candidates with an optimal efficacy 
and toxicology profile before entering clinical trials. 
Considering that the biotechnology sector’s knowledge 
base is both complex and expanding, with widely dis-
persed sources of expertise, the innovation process will 
be found in networks of learning rather than at the 
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enterprise level. Concepts such as open innovation 
(Chesbrough, 2003) imply that firms enjoy permeable 
boundaries. Creativity and innovation can be both spun-
in and -out to and from a firm respectively and thus 
offering a better complementarity with the innovation 
strategy.  
Recent literature on inter-firm collaborations and inno-
vation provides mixed evidence on the effects of exter-
nally acquired assets on firm innovative performance 
(Cockburn and Henderson, 1998; Coombs and Hull, 
1998; Ahuja and Katila, 2001; Prabhu, Chandy and Ellis, 
2005). This study is based on the assumption that the 
integration of processes of technology sourcing, man-
agement of information and knowledge creation help 
increase the likelihood of reaching exploitation and 
securing competitive sustainability for the firm (Figure 
2). We believe because of the uncertain and incremental 
nature of the value added of an early stage technology it 
is essential for biotechnology companies to identify, 
validate, harmonize and integrate complementary and 
mutually supportive technologies in order to improve 
substantially the quality of candidate drugs that enter the 
development stage. The greater ability to identify and 
bring in external technologies enhances a firm’s flexibil-
ity to adapt to uncertain changes in the environments. 
 
Figure 2. Organizational learning process in the drug discovery process 
Figure 2. The key to achieving superior R&D productivity and speed and superior products takes into account a firm’s 
technology sourcing, information management and knowledge creation capabilities. This requires an intra-firm organiza-
tional framework capable of bridging the gap between a firm’s explorative and exploitative capabilities. 
Many biotechnology firms have turned to external 
sourcing strategies and learning alliances in order to gain 
access to novel knowledge and reduce uncertainty in 
R&D. However, we believe in order to strike the ade-
quate balance between exploration and exploitation, 
mergers & acquisitions (M&A) may be the preferred 
choice of external technology acquisition for the discov-
ery and pre-clinical phases of the drug discovery proc-
ess. Other modes of collaborations such as strategic 
alliances collaborations would be more appropriate for 
the development phase of the process. Previous studies 
fail to capture the growing importance of the dynamic 
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nature of such relationships between biotechnology 
companies, engendered by the low R&D output.  
The research outlined in this study suggests that the 
best approach for a research intensive company to 
overcome the dilemma of technological uncertainty is to 
implement an organizational model to combine diversity 
in exploration and integrative capabilities for exploita-
tion. 
2. Literature on external sourcing of know-
ledge 
The implementation of strategies requires a thorough 
understanding of the external environment in terms of 
technology, competition and demand. This perspective 
has underpinned the development of new concepts, 
such as dynamic capabilities (Teece et al., 1997; Deeds 
et al., 2000; Eisenhardt and Martin, 2000; Zollo and 
Winter, 2002). Moreover, the concept of technological 
learning as the process that allows the firm to enhance, 
expand and/or renew its knowledge base and compe-
tences as a response to changes in technology, competi-
tion and demand has been highlighted (Hitt et al. 2000). 
Eisenhardt and Martin (2000) refer to dynamic capabili-
ties as “the firm’s processes that use resources to inte-
grate, reconfigure, gain, and release resources to match 
and even create market change”. 
External technology acquisition has been viewed as an 
important method by firms to achieve higher economic 
returns (Tsai & Wang, 2008). Firms engage in external 
technology acquisition in response to a number of stra-
tegic incentives such as enhancing their knowledge base 
(Ahuja and Katila, 2001; Henderson and Cockburn, 
1996; Rothaermel and Deeds, 2004), adding technologi-
cal elements that increase opportunities for new scien-
tific search (Kim and Kogut, 1996; Rosenkopf and 
Almeida, 2003), or altering their development trajecto-
ries (Mathews, 2003). The learning-based strategy can 
also provide higher visibility in financial markets (Walter 
and Barney 1990).  
The organizational learning literature has recognized 
that formal inter-organizational alliances (ranging from 
licensing, equity participation, R&D consortium, R&D 
agreements to joint ventures) can provide access to the 
knowledge of a partnered organization (Inkpen 2000). 
According to innovation studies, knowledge contributing 
to the development of innovations is regularly obtained 
from outside organizations (Mansfield, 1995). The inter-
action between biotechnology companies has mainly 
taken forms of strategic alliances and M&A transactions. 
2.1. Strategic Alliances 
The field of biotechnology represents a sector with 
most alliances. Biotechnology companies have long re-
lied on pharmaceutical partners using alliances in order 
increase their survival prospects and experience rapid 
growth (Niosi, 2003). Previous studies have highlighted 
the importance and characteristic of strategic alliances 
in a context characterized by technological changes and 
emerging new technologies (Grant and Baden-Fuller, 
2004). In effect, early-stage biotechnology companies 
secure backward vertical alliances with academia to get 
access to basic knowledge and state-of-the-art tech-
nologies and forward vertical alliances with large phar-
maceutical companies to access to complementary 
assets, expertise and financial resources (Galambos and 
Sturchio, 1998; McKelvey et al., 2003). As such, compe-
tencies and expertise in key technologies have been 
rapidly developed in biotechnology companies through 
cooperative alliances.  
Strategic alliances have provided biotechnology compa-
nies with a less costly, less risky and more flexible ap-
proach of accessing new technologies without incurring 
excessive costs. In effect, in the eventuality that the 
outcome of an alliance is unsuccessful the biotechnology 
company can terminate the collaboration in a flexible 
and cost-effective manner. 
Shan, Walker and Kogut (1994) have demonstrated that 
strategic alliances have a positive impact on firm innova-
tiveness. There can be no doubt that alliances are not 
only significant but also acquire an increased strategic 
importance for all new entrants concerned. If anything, 
the high number of alliances reflects first and foremost a 
division of innovative labour in the drug market. Firms 
utilize alliances as learning vehicles for matching its 
competences with the evolving technology, competition 
and demand.  
For small and medium sized firms, the main implication 
is that a strategy focused on learning through alliances 
can significantly reduce the interval between the pro-
duction of scientific knowledge and the commercializa-
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tion of products (Gambardella 1995). A strategy based  
on strategic alliances also helps defray costs and alleviate 
technological and commercial uncertainty (Das and 
Teng, 1996). Perhaps unsurprisingly, firms using alliances 
increase their survival prospects and experience rapid 
growth (Niosi 2003). However, studies have demon-
strated that 30 to 70% of alliances are not successful 
(Kogut 1989; Bleeke and Ernst 1995) 
2.2. Acquisitions 
As a complementary strategy to internal learning and 
learning through alliances, companies may also acquire, 
or merge with other companies (Wernerfelt 1984; Van 
Rooij, 2005) and thus improving long-term survival rates 
(Vermeulen and Barkema 2001). On acquisitions and 
innovation, Prabhu et al (2005) argue that acquisitions 
can be a “tonic” for firm innovative performance. Con-
solidating complementary competences and technolo-
gies has been suggested as an explanation to decrease 
inertia and create synergies through economies of scale 
and scope.  
Zahra (1996) has reported that external technology 
acquisitions is positively associated with firm perform-
ance in terms of sales and market growth. Furthermore, 
Jones at al. (2001) has reported that internally available 
resources enhance the effect of external technology 
acquisition on product performance. 
M&As have often been triggered by the belief that the 
combined value of technology platforms are greater 
than the sum of their parts, in part because the combi-
nation of these competences often allows technology 
platform companies to reduce rigidities by becoming 
fully-integrated drug discovery firms, and in part because 
the very business of conducting innovative activities in 
chemistry, informatics, biology and instrumentation can 
synergize to achieve economies of scope and scale. 
A relevant stream of research has examined comple-
mentarity effects of internal resource development and 
external resource acquisition by arguing that it is such 
complementarities that impact firm innovative perform-
ance (Duysters & Hagedoorn, 2000; Cassiman B, 
Veugelers R. 2006.). Recently, Tsai & Wang (2008) high-
light the importance of internal R&D investment accu-
mulation for firms wishing to gain competence. Also, it 
has been previously demonstrated that accumulating 
internal R&D investment over time, firms can expand 
their technological knowledge or capability (Cohen & 
Levinthal, 1990; Duysters & Hagedoorn, 2000). From a 
drug discovery perspective, a critical capability may be 
the leveraging of diverse knowledge both within and 
across therapeutic areas in the combined firm. (Jung, 
2002). 
Moreover, Mathews (2003) has argued that firms may 
not have the organizational capabilities to realize poten-
tial benefits from the technology acquired thus they are 
confronted with low levels of financial and product 
performance. This aspect was further developed by 
Smith & Sharif (2007) where they highlight the impor-
tant role of human expertise, organizational structure 
and information assets in the acquisition of technology 
assets.  
3. Drug discovery R&D productivity and its 
implications for technology sourcing 
The former head of Smithkline Beecham in 2000 claimed 
that biotechnology had been a bad investment citing 
1,900 clinical failures and only 137 products reaching the 
market for the period between 1985 ad 2000 (Biocen-
tury Extra, 2000). However, several academic studies 
have concluded that drugs developed in an alliance are 
more likely to reach the market than drugs developed 
independently by an originating company. One study 
examined 1,900 compounds developed by over 900 
firms between 1988 and 2000 concluded that drugs 
developed in alliances had a 9 to 14 percent point higher 
probability of successfully completing phase 2 and phase 
3, respectively, than drugs developed by a single com-
pany (Danzon etal., 2005). These positive effects were 
even stronger when the in-licensing firm had consider-
able experience in drug development. Dimasi (2001) 
also arrived at similar results using slightly different 
samples and time periods. 
More recently, Czerepak and Ryser (2008) observed for 
the 2 year period spanning from January 2006 to De-
cember 2007, that 103 products were approved by the 
FDA with 47(45%) originating from the biotechnology 
sector; 16 (16%) were developed through partnerships 
between biotechnology and pharmaceutical companies 
and 40 (39%) were covered by pharmaceutical compa-
nies including 4 that were in-licensed from biotechnol-
ogy companies. However, only 31 of all FDA approvals 
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were novel drugs or new chemical structures with 9 
coming from the biotechnology sector and 5 through 
partnerships and the remaining from the pharmaceutical 
sector. The authors further reported that for each FDA 
approval, there was on average one Phase III failure with 
95% of these failures were products originating from the 
biotechnology sector. When only novel drugs were 
considered the failure rate was even higher with 1,6 
Phase III failures for every approval. Novel drugs devel-
oped by biotechnology companies fared worse, on aver-
age, with 4.7 failures for every approval. Also, the 
authors further observed that the pharmaceutical sector 
had a much better success rate than the biotechnology 
sector in getting drugs approved. Also, it was noted that 
biotechnology-pharmaceutical alliances had significantly 
fewer failures.  
According to Recombinant Capital, an online database 
service monitoring the biotechnology sector, biotech-
nology companies enjoyed the following trend of strate-
gic alliances ever since the year 2000: 534 (2000), 623 
(2001), 640 (2002), 641 (2003), 594 (2004), 642 (2005) 
and 669 (2006). Interestingly, the percentage of late 
stage deals had increased by 10% from 21,5% when 
comparing mean values for years 2001/02 and 2005/06. 
The better success rates obtained for FDA approvals 
from the pharmaceutical sector and alliances result 
mainly because of a pharmaceutical company’s prior 
experience in clinical development and regulatory ex-
pertise that can help them to better evaluate the prob-
ability of success of clinical trials and approval. In effect, 
pharmaceutical companies have the financial strength to 
undertake safety tests in large populations prior to mar-
ket approval. This allows them to avoid misconceptions 
about clinical development that can compromise the 
development and favour diminished quality.  
The biotechnology industry’s low R&D productivity can 
be explained mainly by two reasons: 1) The complexity 
of the drug discovery process and the sector’s incapaci-
ty to plan and integrate processes, enforce data integri-
ty, and better manage resources through a range of 
different technologies; 2) Biotechnology companies 
business models attempt to link technological capabili-
ties to future market needs in a resource constrained 
environment and high investor expectations. The in-
vestment community’s short-term focus and disap-
pointment regarding the sector’s R&D output has 
forced biotechnology companies to bridge the gap be-
tween technological potential and commercialization in 
order to meet those expectations. However, this has 
forced the greatly of them to embark on ill-prepared, 
accelerated and incomplete clinical trials with low quali-
ty products that ultimately experienced failure further 
down the development process.  
4. Coping with a turbulent environment 
Companies deeply involved in outsourcing their re-
search efforts with a variety of different partners, even 
though each being coherent, due to discrepancies in 
data integrity will not be able to fully capitalize on the 
product information flow from one stage to another 
within the value chain of the drug discovery process. 
Furthermore, many of the biotechnology companies 
may not have the organizational capabilities to realize 
potential benefits from the technology acquired. 
But all those companies share common challenges: a 
novel base of technology and a complex context in 
which that the technology must be applied. The posi-
tioning of a technology within the overall drug discovery 
value chain is unique. At the time a drug discovery pro-
gram is initiated, limited data is available regarding the 
R&D project, resources and time required to success-
fully realize the future payoff. However, completing 
successive stages will incrementally reveal data related 
to these matters with increasing visibility regarding the 
barriers to completion.  
Thus, an efficient management of information, knowl-
edge, and organizational learning appears as the principal 
source of competitiveness. In order to secure competi-
tive sustainability biotechnology companies need to 
source and evaluate information; organize and harmo-
nize information, integrate data and process information 
in order to generate knowledge (Figure 3). 
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Figure 3. R&D strategy based on the identification, validation, harmonization, integration and processing of internally co-
herent but mutually supportive technologies contributes to the convergence of innovation. 
The biotechnology company as a learning organization 
must develop the ability to create, acquire and trans-
form knowledge. Learning organizations are provided 
with a network of shared information where empo-
werment is valued as the capacity to transform new 
knowledge into innovations, as shared knowledge is 
processed and implemented. As such, if a firm is to 
increase its chances of survival in a turbulent environ-
ment, it must also achieve the right balance involving the 
exploration of new possibilities and the exploitation of 
old certainties (McNamara and Baden-Fuller 1999).  
4.1. Sourcing 
A company’s ability to choose technologies wisely will 
have a large impact on the performance of its R&D 
organization in terms of time to market, cost-
effectiveness, productivity and product quality. The 
advent of diverse cutting-edge science into biomedical 
research and drug discovery has necessitated a redesign 
of the drug discovery process in the direction of more 
industrialized processes. In effect, the emergence of 
“rational drug design” paradigm in the discovery process 
has created niches for focused and highly specialized 
firms where the expertise is based on a sole technology 
platform or disease indication. Biotechnology companies 
can typically only afford to cover a few technologies and 
therapeutic areas and often find themselves in a situa-
tion of losing their way in the labyrinth of options pre-
sented by the various technologies. In effect, because of 
the distinct disciplines within the industry, knowledge 
acquisition from the development process can be ex-
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tremely high. The explosion of new discovery technolo-
gies necessitates the formation of complementary or-
ganizational structures. 
Moreover, the fact that much of R&D in biotechnology 
is based on incompletely understood living systems such 
as humans, animals, and plants implies that R&D pro-
grams are subject to drastic technological feasibility and 
uncertainty. Each technology is typically only part of the 
larger set of activities in the R&D value delivery system 
in which it participates. The lack of interaction and inte-
gration amongst the various technologies within the 
value chain will favour the development of many un-
promising drug candidates.  
Coordination of such-inter technology extensions at the 
level of the value chain represents the realistic vision of 
value creation learning within the drug discovery proc-
ess. Otherwise in the absence of mutually supportive 
technologies enormous value gets lost. Implementing 
platforms that incorporate other value-adding technolo-
gies has become a pre-requisite for success. The option 
of ignoring such issues will undoubtedly compromise a 
company’s long-term success. 
Companies having a wider view of the drug discovery 
process will be in a better position to exploit external 
knowledge produced. This way companies will avoid any 
short sightedness by overseeing linkages upstream and 
downstream of their own technologies and capabilities. 
4.2. Harmonizing 
The challenges involve in the collection, storage and 
analysis of the large amounts of biological and chemical 
data being produced by high-throughput biology, screen-
ing, profiling and chemical library generation technolo-
gies.  
Standardization is required in order to facilitate informa-
tion exchange based on shared norms between various 
disciplines. Thus, for the advancement of R&D produc-
tivity, harmonization at multiple levels is essential. Mini-
mum information standards for the description of data 
sets and common languages for the description of bio-
logical pathways as well as for the mathematical model-
ling need to be developed.  
As a consequence, the assembly of large integrated 
models providing novel biological insights and the unified 
view of all relevant intelligence information will allow 
the development of techniques to aid scientists in mak-
ing decisions based on accurate information. Most initia-
tives undertaken by biotechnology companies within the 
drug discovery value chain will need to focus on infor-
mation sharing between disparate systems. Even though 
the bulk of current information contains large amounts 
of knowledge, however, it is extremely difficult if not 
possible to gain access to that information. 
Additionally, most of the data models for these systems 
have evolved separately from different sets of require-
ments. To further complicate matters, many different 
companies have implemented systems using different 
products and information models. Thus standards for 
characterization, manufacture and sharing information 
about modular biological devices may lead to a more 
efficient predictable and design driven drug discovery 
process. 
The biological interpretation of the data will be facili-
tated by various tools, which place the analysis results 
into context with existing biological knowledge. Thus, 
efforts to unify and standardize the way in which infor-
mation is recorded should make the interpretation of 
large-scale data experiments easier.  
4.3. Integrating 
The combination of novelty and complexity makes a 
company’s excellence in technology integration critical. 
This need has become even more acute for the tech-
nologies involved in the early phase of the drug discov-
ery process. The integration of biological information 
from various sources, such as large scale data produced 
by various experimental techniques, provides a valuable 
platform for the drug candidate identification and selec-
tion. 
In effect, various technologies utilized within the drug 
discovery value chain are mutually supportive. This 
implies that within the drug discovery value chain com-
panies pursuing R&D activities generate knowledge as 
output that is in turn utilized as input to enhance and 
expand its value-added. The outcome of R&D endeav-
ours of knowledge generation through learning and 
integration provides the right rational and infrastructure 
to sustain a competitive advantage.  
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Such integrated approaches will help the prioritization 
of preclinical drug candidates. As a consequence, drug 
discovery companies are concentrating their efforts on 
approaches to raise the “probability of success” of lead 
candidates in an effort to decrease the rate of attrition 
in the development process. 
4.4. Processing  
The biotechnology sector has been overwhelmed by the 
information explosion in the last several years. As such 
data processing has become essential in managing this 
information overload. The efficient management of in-
formation and knowledge generation consists of incor-
porating novel information, capitalizing on existing 
information and integrating novel and existing informa-
tion in order to create knowledge, and finally putting 
that knowledge into exploitation. 
These activities are executed through the implementa-
tion of technology and organizational structures in or-
der to raise the yield of existing knowledge and produce 
new knowledge (Figure 3). Critical in this effort is in 
acquiring, harmonizing, integrating in order to generate 
knowledge for learning, problem solving, and decision 
making. 
As such knowledge management highlights critical func-
tions and potential bottlenecks which hinder knowledge 
flows to the stage of exploitation. It will ultimately allow 
the biotechnology to protect and enhance its intellectual 
assets, seeks opportunities to improve decisions, servic-
es and products through adding intelligence, increase 
value and provide flexibility. 
5. Implications of technology sourcing on 
business strategy  
The management of knowledge would be the systematic 
process of sourcing, validating, selecting, organizing, 
differentiating and generating knowledge. In other 
words, it attempts to generate and utilize spaces of 
technology interaction that allow the development of 
the intangible assets that support the firm in the 
achievement of its objectives. Thus, gaining and sustain-
ing a competitive advantage requires that a company 
understands the entire value delivery system and not 
just the segment of the value chain in which it partici-
pates. This necessitates the management of competitive 
capabilities at a wider scale and no longer based at a 
firm level based on a sole technology.  
As complex as it might seem to implement platforms 
that incorporate the role of other value-adding tech-
nologies, the option of ignoring these wider issues is 
quickly becoming unrealistic for biotechnology compa-
nies. This evolution requires a fundamental recasting of 
intra and inter-firm organizational frameworks, business 
models and strategic orientations. Firms can increase 
considerably their operational efficiency and R&D pro-
ductivity by providing direction capabilities within the 
technology maze of the drug discovery process.  
In the early stage of the drug discovery process innova-
tion is based on an open network where firms engage in 
efforts to establish direct contacts with all their part-
ners. This creates a situation that ultimately contributes 
to the dispersion of innovation and is characterized by 
high managerial involvement. In effect, different partners 
have access to different flows of information, whilst at 
this stage value is essentially created through a closed 
network where information is exchanged and trans-
formed based on shared norms.  
Achieving this goal is the primary objective of he bio-
technology sector’s efforts to renovate and reinvigorate 
its R&D. Developing technology internally meets the 
needs of capability building for the firm, but it requires 
more time and greater resources. Acquiring technology 
externally constitutes the best alternative for the sector 
which suffers from rapidly changing technology and high 
investor expectations. Such an approach will lead access 
to new knowledge and organizational structures that are 
essential in serving markets of unmet medical needs in 
the most cost-effective and rational way. 
Thus, collaboration amongst biotechnology firms 
through M&A will enable them to diversify risk by secur-
ing options on different projects and allow them to 
deliver quality and innovative products entering clinical 
trials at a faster rate. M&A at the early stages of the 
drug discovery process helps implement an organiza-
tional structure based on a closed network favouring 
knowledge creation through the convergence of innova-
tion which is achieved by the coordination of data col-
lection, validation, screening and processing. Thus, a 
strategy based on M&A will be capable of coordinating 
intra/inter-firm extensions at the level of the value chain 
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and of projecting the pragmatic vision of value creation 
planning within the drug discovery process. 
Access to capital markets and strategic alliances with 
major pharmaceutical companies constitute the two 
major sources of financing for the biotechnology’s sec-
tor. The extremely high financing needs of the tradi-
tional discovery to market business-model can leave 
companies orphaned if investors lose interest along the 
way. In effect, the pressure exercised by the capital 
markets has considerable influence on the nature of the 
dynamics characterizing the biotechnology sector. The 
lack of a financing opportunity from the capital markets 
can jeopardize the viability of a biotechnology company. 
As a consequence, biotechnology companies may find 
themselves in situations where they have to let go of 
value embedded in their R&D programmes or poten-
tially become acquisition targets. To avoid such vulner-
ability companies need to adopt a business model based 
on M&A in order to optimize the time to market aspect 
of drug discovery and development. As such, they will 
be in a position of delivering an earlier return by fully 
capitalizing on their R&D portfolios and by prioritizing 
factors that are financially central in determining the 
long-term success.  
Moreover, major pharmaceutical companies have the 
possibility of choosing among a vast array of technolo-
gies and products in development. As such, major 
pharmaceutical companies entering such collaborative 
arrangements, have the possibility of influencing their 
objective to technology sourcing. In effect, instead of 
managing numerous strategic alliances they prefer deal-
ing with one company enjoying a wide technology plat-
form capable of responding and adapting to their short- 
and medium term needs. The current trend of M&A 
amongst pharmaceutical companies has forced also the 
biotechnology sector to embark on a M&A trend and 
thus allowing them into re-organizing themselves and 
implementing new and more cost-effective resource 
allocation strategies. Recombinant capital reports the 
following figures regarding M&A activity within the bio-
technology sector since 2001: 52 (2001), 36(2002), 48 
(2003), 49 (2004), 50 (2005), 36 (2006) and 52 (2007). 
Such re-organizations are often accompanied by new 
technology portfolio management which could help 
many biotechnology companies access precious sources 
of capital particularly when financial markets are not so 
receptive to the sector. 
If the biotechnology company is to achieve and maintain 
a position of superior productivity, it must also think 
strategically about long-term outcome and devote sig-
nificant resources to R&D. Companies that have imple-
mented strategic orientations in order to secure 
sustainability have shaped and clarified their choices 
within a competitive environment. 
6. Conclusion 
We argue that exploratory technological acquisitions 
help firms gain access to technical knowledge that could 
support innovation. Furthermore, they will lead to asset 
accumulation and the generation of new capabilities in 
relation to the firms’ absorptive capacity. Biotechnology 
companies should support the development of those 
competencies that allow a more effective and significant 
utilization of the information and the knowledge avail-
able. In effect, too many companies start with the tech-
nology itself rather than what they are trying to achieve. 
They do not ask, ‘What is our business strategy? What 
fundamental research questions are we trying to an-
swer? What technologies do we need to answer those 
questions and how will this technology help us to an-
swer them? Ideally, companies need to determine in 
advance technological process required to guarantee the 
success of the product development. In effect, the de-
velopment of innovative therapeutic compounds is 
largely technology driven that necessitates on building 
upon existing technologies until new bottlenecks appear. 
The main question that needs to be answered is to 
determine that how sustainable is the commercial de-
velopment of drugs in drug discovery’s uncertain envi-
ronment where early-stage biotechnology companies 
only have limited expertise? The key to maintaining a 
superior performance here is not only a matter of tech-
nology value-added and differentiation is a matter of 
sustainable competitive dynamics. This is particularly 
true for an environment of great turbulence such as he 
biotechnology sector where technology is subject to 
obsolescence and its outcome uncertain and remote, 
where competition is intense and resources limited 
whilst markets being volatile. In such an environment, 
the firm may rapidly lose it competitive advantage (or 
positioning), so purposeful efforts to enhance, expend 
and renew its competences are often the key to sur-
vival. 
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The organizations that look to manage knowledge gen-
eration within the firm must develop an organizational 
culture in which it is possible to share, integrate and 
transform knowledge. In other words, its business strat-
egy that should dictate the technologies in which the 
company invests. This approach ensures the develop-
ment of a technology platform that genuinely supports 
the product pipeline, which is balanced in terms of risk 
and will deliver a real return on investment (Figure 4). 
Biotechnology companies face difficult and complex 
decisions when identifying, evaluating and selecting new 
technologies to apply to their R&D. The majority of 
technologies that yield truly novel products originate in 
other companies and often in other industries. The 
most effective technological advancements often unite 
concepts and components from diverse areas including 
physics, chemistry, biology, electronics, engineering, 
computer science, material science, optics, micro-
fabrication and information science.  
 
Figure 4. The objective for a biotechnology company is to provide definitive answers in early stages of the drug discovery 
process by increasing the attrition rates of low quality products and favouring the entrance of promising products into 
clinical development.
Considering the long product development time lines 
the contribution of external technology acquisition to 
firm performance cannot be measured using traditional 
performance indicators. Technology sourcing in the 
dynamic nature of the biotechnology industry can be 
used as learning vehicles for matching its competences 
with the evolving technology, competition and demand.  
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